AZTherapies
Clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$105—158m (Dealroom.co estimates Oct 2019.)
Boston Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $5.1m | Seed | |
N/A | $9.2m | Early VC | |
$17.0m | Series A | ||
N/A | $6.5m | Convertible | |
N/A | $6.6m | Convertible | |
N/A | $23.8m | Series B | |
$26.3m | Series C | ||
$11.2m Valuation: $132m | Series C | ||
Total Funding | $106m |
Recent News about AZTherapies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.